[
  {
    "ts": null,
    "headline": "This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?",
    "summary": "Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions.  This new coverage could also make it easier once CRISPR Therapeutics earns approval for other gene-editing medicines.",
    "url": "https://finnhub.io/api/news?id=a1c5818b50b560ef8a8831517730c6a5d6c5136684913c6ee10214e50685a655",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734888300,
      "headline": "This Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?",
      "id": 132112267,
      "image": "https://g.foolcdn.com/editorial/images/800098/physician-giving-a-high-five-to-a-young-patient.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions.  This new coverage could also make it easier once CRISPR Therapeutics earns approval for other gene-editing medicines.",
      "url": "https://finnhub.io/api/news?id=a1c5818b50b560ef8a8831517730c6a5d6c5136684913c6ee10214e50685a655"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November.  The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.  Meanwhile, Vertex is heading for two pieces of news in January that could be enormous for the company.",
    "url": "https://finnhub.io/api/news?id=9cf02dbce7fd15aa07371d1ed2ae24b7247ab84c9cf459d146c022f7614b6cd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734859800,
      "headline": "Should You Buy Vertex Pharmaceuticals on the Dip Before Potentially Enormous News in January 2025?",
      "id": 132107420,
      "image": "https://g.foolcdn.com/editorial/images/801725/gettyimages-research-team-smiles-in-lab.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) was on track to become one of this year's biotech winners, with the shares climbing 27% from January through a peak in November.  The company, the global leader in cystic fibrosis (CF) treatments, has established a long track record of earnings growth thanks to this business -- and in recent times has made significant progress on broadening into other billion-dollar treatment areas.  Meanwhile, Vertex is heading for two pieces of news in January that could be enormous for the company.",
      "url": "https://finnhub.io/api/news?id=9cf02dbce7fd15aa07371d1ed2ae24b7247ab84c9cf459d146c022f7614b6cd5"
    }
  }
]